| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RANk |
| Uniprot No | Q9Y6Q6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-313aa |
| 氨基酸序列 | QIAPPCTSEKHYEHLGRCCNKCEPGKYMSSKCTTTSDSVCLPCGPDEYLDSWNEEDKCLLHKVCDTGKALVAVVAGNSTTPRRCACTAGYHWSQDCECCRRNTECAPGLGAQHPLQLNKDTVCKPCLAGYFSDAFSSTDKCRPWTNCTFLGKRVEHHGTEKSDAVCSSSLPARKPPNEPHVYLPGLIILLLFASVALVAAIIFGVCYRKKGKALTANLWHWINEACGRLSGDKESSGDSCVSTHTANFGQQGACEGVLLLTLEEKTFPEDMCYPDQGGVCQGTCV |
| 预测分子量 | 55 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RANK(Receptor Activator of Nuclear Factor κB)重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Osteoclast differentiation and activation by RANKL: A story of modulation*
**作者**：Lacey, D. L., et al.
**摘要**：该研究阐明了RANKL(RANK配体)与RANK受体结合在破骨细胞分化与激活中的核心作用。作者通过重组RANK蛋白实验，证明RANKL-RANK信号通路是骨吸收的关键调节机制，并探讨了其在骨质疏松等疾病中的潜在治疗靶点。
---
2. **文献名称**：*RANK signaling in immune system development*
**作者**：Kong, Y. Y., et al.
**摘要**：该文献揭示了RANK重组蛋白在免疫细胞(如树突状细胞和T细胞)发育中的功能。研究发现，RANK信号不仅调控骨代谢，还通过调节淋巴器官微环境影响免疫耐受和自身免疫疾病的病理过程。
---
3. **文献名称**：*Engineering and applications of recombinant RANK extracellular domain*
**作者**：Nakagawa, N., et al.
**摘要**：文章报道了一种重组RANK胞外结构域蛋白的制备方法，并验证其作为RANKL拮抗剂的活性。实验表明，该重组蛋白可阻断RANKL诱导的破骨细胞生成，为开发抗骨吸收药物提供了新策略。
---
如需更多文献或特定研究方向，可进一步补充说明。
**Background of RANK Recombinant Protein**
Receptor Activator of Nuclear Factor κ B (RANK), encoded by the *TNFRSF11A* gene, is a transmembrane protein belonging to the tumor necrosis factor receptor (TNFR) superfamily. It plays a critical role in regulating osteoclast differentiation, bone remodeling, and immune system modulation. RANK interacts with its ligand, RANKL (RANK ligand), to activate downstream signaling pathways, including NF-κB and MAPK, which are essential for osteoclastogenesis and bone resorption. Dysregulation of the RANK-RANKL axis is linked to bone-related disorders such as osteoporosis, rheumatoid arthritis, and cancer-induced bone metastases.
Recombinant RANK protein is engineered in vitro using expression systems like mammalian, insect, or bacterial cells. This protein retains the extracellular domain of RANK, enabling studies on ligand-receptor interactions, signaling mechanisms, and drug development. Researchers use RANK recombinant proteins to screen inhibitors (e.g., denosumab, a monoclonal antibody targeting RANKL) or to investigate cross-talk between bone metabolism and immune cells.
Therapeutic targeting of RANK signaling has transformed osteoporosis treatment and is being explored in oncology to prevent skeletal complications. Additionally, RANK recombinant proteins serve as tools to study autoimmune diseases and lymph node development, given RANK's role in T-cell tolerance and dendritic cell survival. Its structural and functional versatility underscores its importance in both basic research and clinical applications.
×
